GERMANTOWN, Md.–(BUSINESS WIRE)–Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Jefferies Healthcare Conference in New York, NY.
Management is scheduled to present on Thursday, June 9, 2022 at 1:30pm ET. Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.
About Senseonics
Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM systems, Eversense®, Eversense® XL and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.
Contacts
Senseonics Investor Relations Contact:
Philip Taylor
Investor Relations
415-937-5406
Investors@senseonics.com
Halifax, Nova Scotia--(Newsfile Corp. - March 18, 2024) - Sona Nanotech Inc. (CSE: SONA), (OTCQB:…
LITTLETON, Colo.--(BUSINESS WIRE)--Rare Element Resources Ltd. (the “Company” or “RER”) (OTCQB: REEMF) is pleased to…
Significant increase in number of points of sale (100%) for Happy Caps Mushroom Home Grow…
- Project To Increase RNAP Manufacturing Capacity and Reduce Unit Costs of Goods -- Project…
NEWARK, CA / ACCESSWIRE / March 18, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the…
PharmAla now first company to supply both MDMA and Psilocybin into the Australian MarketVANCOUVER, British…
